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Hypoxia-Inducible Transcription Factor 2a Promotes
Steatohepatitis Through Augmenting Lipid
Accumulation, Inflammation, and Fibrosis
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Frank J. Gonzalez,1 and Yatrik M. Shah2,3
Oxygen dynamics in the liver is a central signaling mediator controlling hepatic homeosta-
sis, and dysregulation of cellular oxygen is associated with liver injury. Moreover, the tran-
scription factor relaying changes in cellular oxygen levels, hypoxia-inducible factor (HIF), is
critical in liver metabolism, and sustained increase in HIF signaling can lead to spontaneous
steatosis, inflammation, and liver tumorigenesis. However, the direct responses and genetic
networks regulated by HIFs in the liver are unclear. To help define the HIF signal-transduc-
tion pathway, an animal model of HIF overexpression was generated and characterized. In
this model, overexpression was achieved by Von Hippel-Lindau (Vhl) disruption in a liver-
specific temporal fashion. Acute disruption of Vhl induced hepatic lipid accumulation in an
HIF-2a–dependent manner. In addition, HIF-2a activation rapidly increased liver inflam-
mation and fibrosis, demonstrating that steatosis and inflammation are primary responses of
the liver to hypoxia. To identify downstream effectors, a global microarray expression analy-
sis was performed using livers lacking Vhl for 24 hours and 2 weeks, revealing a time-
dependent effect of HIF on gene expression. Increase in genes involved in fatty acid synthesis
were followed by an increase in fatty acid uptake-associated genes, and an inhibition of fatty
acid b-oxidation. A rapid increase in proinflammatory cytokines and fibrogenic gene expres-
sion was also observed. In vivo chromatin immunoprecipitation assays revealed novel direct
targets of HIF signaling that may contribute to hypoxia-mediated steatosis and inflamma-
tion. Conclusion: These data suggest that HIF-2a is a critical mediator in the progression
from clinically manageable steatosis to more severe steatohepatitis and liver cancer, and may
be a potential therapeutic target. (HEPATOLOGY 2011;54:472-483)
O
xygen is a critical signaling molecule that reg-
ulates the metabolic activities of the liver.1,2
Dysregulation of the normal oxygen gradient
in the liver can induce liver steatosis and inflamma-
tion.2 Decreased cellular oxygen affects gene expression
through the transcription factor, hypoxia-inducible fac-
tor (HIF). During normal cellular oxygen levels, HIFa
subunits are rapidly degraded by the ubiquitin protea-
some system in which Von Hippel-Lindau (VHL)
tumor suppressor protein is the critical E3 ubiquitin
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Received February 28, 2011; accepted April 17, 2011.
This study was supported by grants from the National Institutes of Health (CA148828), The University of Michigan Gastrointestinal Peptide Center (to
Y.M.S.), and the National Cancer Institute Intramural Research Program.
Address reprint requests to: Yatrik M. Shah, Ph.D., Department of Molecular and Integrative Physiology, Department of Internal Medicine, Division of
Gastroenterology, University of Michigan, 1301 East Catherine Street, Ann Arbor, MI 48109. E-mail: shahy@umich.edu; fax: 734-936-8813.
472
ligase required for HIF degradation.3-8 HIF-1a and
HIF-2a regulate the expression of genes critical for ad-
aptation to low oxygen levels. Targeted disruption of
Vhl in the liver increased HIF-1a and HIF-2a expres-
sion, and this mouse model has demonstrated that
HIFs are critical in erythropoiesis, iron metabolism,
hepatic lipid homeostasis, glucose metabolism, and
tumor formation in the liver.9-14 Because overexpres-
sion of HIF through disruption of Vhl has many ro-
bust pleiotropic effects, it is difficult to assess which
are the direct responses of the liver after hypoxia. Fur-
thermore, finding direct mediators of HIF signaling in
the liver, which contribute to the phenotype, has been
difficult. To overcome this problem, we describe a
liver-specific temporal disruption of Vhl using a cre-
ERT2 system, which activates a liver-specific cre recom-
binase expression in the presence of the estrogen ana-
log, tamoxifen. Acute disruption of Vhl resulted in a
robust accumulation of lipids in the liver and an
increase in liver inflammation and fibrosis. Using a
compound double deletion of Vhl and Hif-1a or Hif-
2a, liver steatosis, inflammation, and fibrosis were
mediated in a HIF-2a–dependent manner. To assess
direct signaling pathways activated by HIF, global gene
expression analysis was performed in the livers of mice
with a temporal disruption of Vhl for 24 hours or 2
weeks. Gene expression profiles demonstrated that HIF
rapidly regulates a large battery of genes important for
fatty acid synthesis, uptake, and b-oxidation. Moreover,
several proinflammatory mediators and profibrogenic
genes were rapidly activated after Vhl deletion. These
data demonstrate that liver injury resulting from hy-
poxia is a primary response mediated by HIF-2a.
Materials and Methods
Luciferase Assay. The mouse angiopoietin-like 3
(Angptl3)-promoter luciferase was previously described.15
Mouse transglutaminase 2 (Tgm2)-reporter plasmid was
constructed by cloning the upstream regions into pGL3-
basic vector (Promega, Madison, WI), using primers
listed in Supporting Table 1. These luciferase reporters
were transfected into Hepa-1 cells, and luciferase assays
were performed as previously described.16
Animals and Diets. VhlF/F, VhlF/FHif-1aF/F, and
VhlF/FHif-2aF/F were previously described.16 For tem-
poral hepatocyte-specific disruption, VhlF/F, VhlF/FHif-
1aF/F, and VhlF/FHif-2aF/F mice were crossed with
mice harboring the Cre-ERT2 recombinase under con-
trol of the albumin promoter, SA-Cre-ERT2.17 The
mice are a mixed Sv129 and C57BL/6 background,
and wild-type littermate control mice were used as a
comparison for each experiment. Mice were used
between the ages of 6 and 8 weeks for all experiments.
For activation of the SA-Cre-ERT2 recombinase for short-
term experiments (i.e., 1 and 3 days), mice were treated
with 1 dose of tamoxifen (2 mg/mouse in corn oil) by
intraperitoneal (IP) injection and killed 24 hours or 3
days after tamoxifen treatment. For the 7-day and 2-week
experiments, mice were fed tamoxifen in the diet for 2
days, then replaced with regular chow and killed at 7
days or 2 weeks after initial tamoxifen administration.
For the alcohol treatment, mice were treated with tamoxi-
fen by IP injection on 2 consecutive days, then were fed,
ad libitum, a 4% alcohol-containing liquid diet (Lieber-
DeCarli Diet; Dyets, Inc., Bethlehem, PA) and killed 2
weeks after alcohol administration. Mice were housed in
temperature- and light-controlled rooms and were given
water and pelleted chow ad libitum. All animal studies
were carried out in accordance with guidelines and
approved by the National Cancer Institute and University
of Michigan Animal Care and Use Committee.
RNA Analysis. RNA was extracted from tissues,
reverse transcribed, and quantitative real-time reverse-
transcriptase polymerase chain reaction (qRT-PCR)
was performed using primer sequences listed in Sup-
porting Table 1.
Western Blot Analysis. Liver whole-cell or nuclear
extracts were prepared. Membranes were incubated
with antibodies against HIF-1a, HIF-2a (Novus Bio-
logicals, Littleton, CO), ANGPTL3 (Santa Cruz Bio-
technology, Inc., Santa Cruz, CA), and smooth muscle
actin (SMA) (Sigma, St. Louis, MO), phophorylated,
and total acetyl-CoA carboxylase (ACC) (Cell Signal-
ing Technology, Beverly, MA) signals obtained were
normalized to GAPDH (Santa Cruz) for whole cell
extract and histone H1 (Santa Cruz), pregnane X re-
ceptor (PXR), and hepatic nuclear factor 4 (HNF-4a)
(Abcam, Cambridge, MA) for nuclear extracts.
cDNA Microarray Analysis. Liver cDNAs were
hybridized to an Agilent 44 K mouse 60-peptide
oligomer microarray (Agilent Technologies, Santa Clara,
CA). Data were processed and analyzed by a Genespring
GX software package (Agilent Technologies).
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Immunohistochemistry. Hematoxylin and eosin
(H&E) and Masson’s trichrome staining were per-
formed on formalin fixed paraffin embedded sec-
tions. Oil red O staining was performed on frozen
liver sections or adherent hepatoma-derived Hepa-1
cells. For quantification of oil red O in Hepa-1 cells,
isopropanol was added to the cells after staining.
Absorbance was measured at 510 nm in the iso-
propanol extracts, and values were normalized to
protein content.
Triglyceride and Cholesterol Analysis. Hepatic lip-
ids were extracted using a 2:1 chloroform-methanol
solution. Liver and serum triglycerides were measured
using the Serum Triglyceride and Cholesterol Determi-
nation Kit, according to the manufacturer’s recommen-
dation (Wako, Richmond, VA).
ChIP Assays. Livers were cross-linked in 1% form-
aldehyde in 1 phosphate-buffered saline at 37C for
20 minutes. ChIP assays were performed for HIF-2a
as previously described.16 Primers for qRT-PCR ChIP
are available upon request. The primers for Tgm2
ChIP are listed in Supporting Table 1.
Data Analysis. Results are expressed as mean 6
standard deviation (SD). P values were calculated by in-
dependent t test. P < 0.05 was considered significant.
Results
Generation of a Mouse Model Containing a Tem-
poral Hepatocyte-specific Disruption of Vhl. VhlF/F
mice were crossed with SA-Cre-ERT2 transgenic mice
to generate a temporal and conditional disruption of
Vhl (VhlF/F;AlbERcre). The tamoxifen-inducible Cre pro-
vides an advantage of assessing immediate downstream
pathways controlled by VHL and eliminates the con-
founding developmental effects of Vhl deletion. To
confirm the inducibility and hepatocyte-specific disrup-
tion, VhlF/F and VhlF/F;AlbERcre mice were treated with
one dose of vehicle or tamoxifen, and livers and extra-
hepatic tissues were isolated 24 hours post-treatment.
VhlF/F and VhlF/F;AlbERcre mice treated with vehicle did
not demonstrate a decrease in Vhl gene expression,
whereas tamoxifen treatment dramatically decreased
Vhl gene expression in the VhlF/F;AlbERcre but not the
VhlF/F mice (Fig. 1A). Moreover, the decrease was spe-
cific for the liver; no other tissues assessed demon-
strated a tamoxifen-dependent decrease in Vhl expres-
sion (Supporting Fig. 1). Western blot analysis of
nuclear extracts demonstrated an increase in HIF-1a
and HIF-2a expression (Fig. 1B). Consistent with
HIFa subunit expression, an increase in pyruvate dehy-
drogenase kinase 1 (Pdk1) and erythropoietin (Epo),
two well-characterized HIF-1a and HIF-2a target
genes, were observed (Fig. 1C). In mice that contained
a conditional disruption of Vhl, increased liver and
spleen weights were noted at 6-8 weeks of age.9,11
Therefore, to assess whether these were early events
after loss of VHL, liver and spleen weights were mea-
sured in mice in which Vhl was disrupted for 14 days.
A significant increase in liver and spleen weights was
observed (Fig. 1D-F). Together, these data demonstrate
that tamoxifen-inducible Vhl disruption is an optimal
system to assess primary responses, which are critical
in hypoxia-induced liver injury.
HIF-2a Increases Inflammation and Lipid Accu-
mulation in the Liver. Conditional inactivation of
Vhl in hepatocytes results in liver inflammation and
hepatic steatosis.9,11,14 However, it is not clear whether
inflammation and lipid accumulation are early events
after disruption of Vhl or are results of the develop-
mental or chronic effects from loss of Vhl. To address
these questions, livers were analyzed after disruption of
Vhl for 2 weeks; a robust increase in liver inflamma-
tion was observed by H&E staining and qRT-PCR
analysis of two proinflammatory mediators: interleu-
kin-1b (Il-1b) and Il-6 (Fig. 2A-C). The increase in
Il-6 and Il-1b gene expression was evident as early as
3 days after tamoxifen treatment (Fig. 2D). Overt
inflammation, as observed by H&E staining, was evi-
dent at 7 days after tamoxifen treatment (Supporting
Fig. 2A). To assess the influence of HIF-dependent
pathways on inflammatory gene expression in the liver,
mice with a double disruption of Vhl and Hif-1a or
Hif-2a were generated. The double disruption of Vhl
and Hif-2a (VhlF/FHif2aF/F;AlbERcreþtamoxifen) ame-
liorated the increase in Il-6 and Il-1b, compared to lit-
termate controls (VhlF/FHif2aF/Fþtamoxifen) (Fig. 2E).
In contrast, a significant increase in Il-6 and Il-1b
gene expression was observed in mice with a double
disruption of Vhl and Hif-1a, compared to littermate
controls (Supporting Fig. 2B). Furthermore, 2 weeks
after the loss of Vhl, a dramatic increase in liver lipid
accumulation was observed by oil red O staining
(Fig. 3A,B). The increase in lipid accumulation could
be observed as early as 24 hours after Vhl disruption
(Fig. 3C,D). The compound disruption of Vhl and
Hif-1a or Hif-2a demonstrated that the increase in
lipid accumulation was caused by HIF-2a, but not
HIF-1a (Fig. 3E,F). Consistent with oil red O stain-
ing, hepatic triglycerides and cholesterol increased after
disruption of Vhl for 2 weeks (Fig. 3G). Together,
these data demonstrate that HIF-2a is a direct regula-
tor of liver inflammation and lipid accumulation in
the liver.
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HIF-Regulated Genetic Program in the Liver. To
understand the critical genes regulated after Vhl disrup-
tion, gene expression profiles of VhlF/F and VhlF/F;AlbERcre
were assessed in livers isolated 24 hours or 2 weeks after
Vhl disruption. In total, 3597 significantly regulated
changes were identified after 2 weeks of Vhl deletion,
whereas 470 genes were identified 24 hours after Vhl dis-
ruption (Fig. 4A; the full gene list with an average
change of 1.5-fold is in Supporting Tables 2 and 3). The
data suggested that a rapid increase in genes critical for
lipid synthesis was followed by an increase in genes im-
portant for fatty acid uptake. Consistent with the micro-
array data, an increase was observed in the expression of
fatty acid synthase (Fasn) and sterol regulatory element
binding factor-1C (Srebp-1c) at 3 days after Vhl disrup-
tion. Interestingly, at 14 days after Vhl disruption, a sig-
nificant repression of Fasn and Srebp-1c was observed
(Fig. 4B), whereas a rapid repression of Cd36 gene
expression was observed after 3 days of Vhl disruption,
followed by a dramatic increase in gene expression 14
days after the loss of Vhl (Fig. 4B). In addition, a signifi-
cant decrease was observed in genes critical in fatty acid
b-oxidation, and a decrease in carnitine palmitoyltransfer-
ase 1A (Cpt1a), carnitine palmitoyltransferase 2 (Cpt2),
acyl-CoA oxidase 1 (Acox), and peroxisome proliferator-
activated receptor alpha (Ppara) were observed after 2
Fig. 1. Conditional and temporal disruption of Vhl in hepatocytes leads to HIF-1a and HIF-2a activation. (A) qRT-PCR analysis measuring liver
Vhl expression in VhlF/F;AlbERcre or VhlF/F mice treated with vehicle (VEH) or tamoxifen (TM) and killed 24 hours post-treatment. Expression was
normalized to b-actin. Seven to nine mice were assessed per each treatment group. (B) Western blot analysis in liver nuclear extracts in VhlF/
F;AlbERcre mice treated with VEH and TM and killed 24 hours and 3 days post-treatment. Expression was normalized to Histone H1 protein expres-
sion. (C) qRT-PCR analysis measuring liver pyruvate dehydrogenase kinase 1 (Pdk1) and erythropoietin (Epo) expression in VhlF/F;AlbERcre mice
treated with VEH or TM at 3 days post-treatment. Expression was normalized to b-actin. Seven to nine mice were assessed per each treatment
group. (D) Liver weight analysis in VhlF/F;AlbERcre or VhlF/F mice treated with VEH or TM and killed 14 days post-treatment. Liver weights were nor-
malized to body weights. Seven to nine mice were assessed per each treatment group. (E,F) Spleen weight analysis in VhlF/F;AlbERcre or VhlF/F
mice treated with VEH or TM and killed 14 days post-treatment. (F) Spleen weights were normalized to body weights. Seven to nine mice were
assessed per each treatment group. Each bar graph represents the mean value 6 SD. *P < 0.05.
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weeks of Vhl disruption; Ppara expression did not
reach statistical significance (Fig. 4C). Interestingly, the
expression of PPARa protein was significantly
decreased 2 weeks after Vhl disruption, suggesting
enhanced degradation (Fig. 4D). Expression of two
other important nuclear receptors, PXR and HNF-4a,
was unchanged. The decrease in b-oxidation genes was
not observed at 3 days after Vhl disruption, but was
dependent on HIF-2a expression (Supporting Fig. 3).
These data suggest that HIF-2a regulates fatty acid
synthesis, uptake, and b-oxidation in a time-dependent
manner.
HIF-2a Is a Novel Regulator of Angptl3. SREBP-
1c, FASN, CD36, and PPARa have critical roles of in
fatty acid homeostasis in the liver; however, their gene-
expression patterns suggest that these genes may not
be direct targets for HIF-2a in the liver. Interestingly,
angiopoietin-like 3 (Angptl3) demonstrated rapid, sus-
tained increase after Vhl disruption (Fig. 5A).
ANGPTL3 is specifically expressed in the liver and is a
direct regulator of lipid homeostasis.18-20 Mutations in
Angptl3 in mice or humans are associated with low se-
rum lipid levels, whereas overexpression of ANGPTL3
increases circulating lipid levels.18,20 In mice with a
double disruption of Vhl and Hif-2a, it was demon-
strated that the induction of Angptl3 was the result of
HIF-2a increase (Supporting Fig. 4). Gene-expression
data correlated to an increase in protein expression, as
tamoxifen-treated VhlF/F;AlbERcre mice demonstrated an
increase in liver ANGPTL3 protein expression, com-
pared to tamoxifen-treated VhlF/F mice (Fig. 5B).
Because mouse models that overexpress ANGPTL3
demonstrated an increase in serum lipid levels,20 serum
triglycerides were assessed in mice 2 weeks after the
loss of Vhl. VhlF/F;AlbERcre mice treated with tamoxifen
had elevated serum triglycerides, compared to similarly
Fig. 2. HIF-2a induces liver inflammation.
H&E-stained liver sections from (A) VhlF/F and
(B) VhlF/F;AlbERcre mice treated with tamoxifen
(TM) and killed 14 days post-treatment. Seven
to nine mice were assessed per each treat-
ment group. (C) qRT-PCR analysis measuring
liver Il-6 and Il-1b expression in VhlF/F and
VhlF/F;AlbERcre mice treated with vehicle (VEH)
or TM and killed 14 days post-treatment.
Expression was normalized to b-actin. Seven
to nine mice were assessed per each treat-
ment group. (D) qRT-PCR analysis measuring
liver Il-6 and Il-1b expression in VhlF/F and
VhlF/F;AlbERcre mice treated with TM and killed
3, 7, and 14 days post-treatment. Expression
was normalized to b-actin. Seven to nine
mice were assessed per each treatment
group. (E) qRT-PCR analysis measuring liver Il-
6 and Il-1b expression in VhlF/FHif2aF/F and
VhlF/FHif2aF/F;AlbERcre mice treated with TM
and killed 14 days post-treatment. Expression
was normalized to b-actin. Seven to nine
mice were assessed per each treatment
group. Each bar graph represents the mean
value 6 SD. *P < 0.05.
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treated VhlF/F mice (Fig. 5C). In addition, liver-
derived Hepa-1 cells, which overexpress ANGPTL3,
demonstrated a dose-dependent increase in oil red O
accumulation, suggesting that ANGPTL3 may play a
critical role in HIF-mediated lipid accumulation (Fig.
5D). To assess whether ANGPTL3 could be a novel
direct target of HIF-2a, Angptl3-promoter luciferase
assays were performed. A 1.7-kilobase (kb) Angptl3
proximal promoter luciferase construct was transfected
into Hepa-1 cells. Hypoxia (1% O2) induced luciferase
expression (Fig. 5E), and cotransfection with a mam-
malian expression plasmid for HIF-1a moderately
increased luciferase expression, whereas cotransfection
with HIF-2a expression plasmid strongly increased lucif-
erase expression. The HIF-1a and HIF-2a increase in
luciferase expression was further potentiated in cells incu-
bated in 1% O2 (Fig. 5E). Deletion analysis showed that
the HIF-responsive site on the Angptl3 promoter was
within the first 100 bp (base pairs) of the proximal pro-
moter; however, no consensus HIF response element
(HRE) was found in this site (Fig. 5F). Furthermore,
in vivo ChIP assays failed to demonstrate HIF-2a bind-
ing to the promoter (data not shown). Together, these
data suggest that Angptl3 is a rapid HIF-2a responsive
gene through a yet-unknown mechanism.
HIF-2a Regulates Liver Fibrogenesis. A dramatic
induction of genes important in liver fibrosis were
observed in the gene-expression profiling data.
Increases in several fibrogenic genes were confirmed in
VhlF/F;AlbERcre mice treated with tamoxifen, compared
to littermate control mice (Fig. 6A). A specific increase
in lysyl oxidase-like 1 (LOXL1), lysyl oxidase-like 2
(LOXL2), prolyl 4-hydroxylase alpha 1 (P4HA1),
prolyl 4-hydroxylase alpha 2 (P4HA2), procollagen-
lysine, 2-oxoglutarate 5-dioxygenase 2 (PLOD2), and
transglutaminase 2 (TGM2) was observed. These genes
are critical for the formation and stabilization of colla-
gen.21-26 In addition, smooth muscle actin (SMA), a
Fig. 3. HIF-2a increases lipid
accumulation in the liver. Oil red O
staining of livers isolated from VhlF/F
and VhlF/F;AlbERcre mice treated with
tamoxifen (TM) and killed (A,B) 14
days or (C,D) 24 hours post-treat-
ment. (E,F) Oil red O staining of livers
isolated from (E) VhlF/FHif1aF/F;AlbERcre
and (F) VhlF/FHif2aF/F;AlbERcre mice
treated with TM and killed 14 days
post-treatment. (G) Hepatic lipid anal-
ysis was performed in livers isolated
from VhlF/F and VhlF/F;AlbERcre mice
treated with TM and killed 14 days
post-treatment. Each bar graph repre-
sents the mean value 6 SD. *P <
0.05. Five to seven mice were
assessed per each treatment group.
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marker of stellate cell activation and fibrosis, was signifi-
cantly increased in VhlF/F;AlbERcre mice treated with ta-
moxifen, compared to littermate control mice, as assessed
by qRT-PCR and western blot analysis (Fig. 6A,B). To
confirm an increase in fibrosis, Masson’s trichrome stain-
ing was performed (Fig. 6C,D). Livers isolated from
VhlF/F;AlbERcre mice 14 days after tamoxifen treatment
demonstrated a moderate increase in focal areas of fibro-
sis, compared to similarly treated VhlF/F mice (Fig. 6C).
Moreover, VhlF/F and VhlF/F;AlbERcre mice were treated
with tamoxifen, then put on liquid diet consisting of 4%
ethanol for 2 weeks. Mice are resistant to alcohol-
induced fibrosis, as chronic treatment with alcohol (i.e.,
over 3 months) typically results in no marked liver fibro-
genesis in mice.27 However, in mice with a disruption
of liver Vhl, alcohol treatment caused marked fibrosis,
compared with littermate controls treated with alcohol
(Fig. 6D). The double disruption of Vhl and Hif-2a
(VhlF/FHif2aF/F;AlbERcreþtamoxifen) ameliorated the
increase in SMA, whereas a significant increase in SMA
expression was observed in mice with a double disrup-
tion of Vhl and Hif-1a (VhlF/FHif1aF/F;AlbERcreþ
tamoxifen) (Fig. 7A). Similarly, the increase in fibrosis
observed in Vhl-disrupted mice on an alcohol diet was
completely lost in the Vhl and Hif-2a double knock-
out, but not the Vhl and Hif-1a double knockout
(Fig. 7B). Consistent with the role of HIF-2a in exac-
erbating fibrosis, fibrogenic gene-expression levels were
not increased in the Vhl and Hif-2a knockout, as com-
pared to mice with a Vhl disruption (Fig. 7C). To-
gether, these data demonstrate that HIF-2a is a critical
transcription factor in exacerbating fibrosis in the liver.
HIF-2a Directly Regulates Several Profibrogenic
Genes. To assess whether HIF-2a could directly regu-
late fibrogenic genes in the liver, ChIP assays were
performed using cross-linked liver DNA isolated from
tamoxifen-treated VhlF/F and VhlF/F;AlbERcre mice, with
the average shearing size of 1.5 kb. Primers were
designed to the center of the proximal promoter to
assess HIF-2a occupancy. This method provides an
assessment of HIF-2a occupancy at promoters without
defining the precise HIF response element. With this
Fig. 4. HIF-2a modulates lipid homeostatic genes in the liver. (A) Global gene-expression profiling was assessed in liver RNAs isolated from
VhlF/F and VhlF/F;AlbERcre mice treated with tamoxifen (TM) and killed 24 hours or 14 days post-treatment. Four mice were used for each treatment
group. (B) qRT-PCR analysis of sterol regulatory element binding factor-1C (Srebp-1c), fatty acid synthase (Fasn), and Cd36 in livers from VhlF/F
and VhlF/F;AlbERcre mice treated with TM and killed 3 or 14 days post-treatment. Expression was normalized to b-actin. (C) qRT-PCR analysis of
b-oxidation genes, carnitine palmitoyltransferase 1A (Cpt1a), carnitine palmitoyltransferase 2 (Cpt2), acyl-CoA oxidase 1 (Acox), and peroxisome
proliferator-activated receptor alpha (Ppara) in livers from VhlF/F and VhlF/F;AlbERcre mice treated with TM and killed 14 days post-treatment.
Expression was normalized to b-actin. Seven to nine mice were assessed per each treatment group. (D) Western blot analysis measuring PPARa,
pregnane X receptor (PXR), and hepatic nuclear factor 4 (HNF-4a) expression from livers in VhlF/F and VhlF/F;AlbERcre mice treated with TM and
killed 14 days post-treatment. Each bar graph represents the mean value 6 SD. *P < 0.05.
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method, it was shown that HIF-2a was enriched at the
promoters of several fibrogenic genes in VhlF/F;AlbERcre
mice, compared with control littermates (Fig. 8A). To
assess whether the low-resolution ChIP assays, indeed,
did identify direct targets, TGM2 expression was fur-
ther assessed. An increase in TGM2 protein expression
was observed in VhlF/F;AlbERcre mice, compared to con-
trol littermates, after 2 weeks of Vhl disruption (Fig.
8B). Next, a Tgm2 proximal promoter luciferase con-
struct was cotransfected into liver-derived Hepa-1 cells
with a mammalian expression plasmid for HIF-1a, HIF-
2a, or empty vector. HIF-2a specifically induced lucifer-
ase expression, whereas HIF-1a had no effect, compared
with empty vector transfected control (Fig. 8C), and
mutating the two putative HREs ablated HIF-2a activity
(Fig. 8D). Using primers flanking the HREs and sheared
cross-linked liver DNA (shearing size, 300 bp) from
tamoxifen-treated VhlF/F and VhlF/F;AlbERcre mice demon-
strated increased HIF-2a binding to the Tgm2 promoter
in livers isolated from VhlF/F;AlbERcre mice, compared to
VhlF/F mice (Fig. 8E). These data demonstrate that HIF-
2a can directly regulate fibrogenic genes.
Discussion
One-third of adults in the United States are diag-
nosed with fatty liver disease, mostly attributed to obe-
sity or alcohol consumption. Approximately 10% will
proceed to develop steatohepatitis and associated
comorbidities (e.g., fibrosis, cirrhosis, and liver can-
cer).28 Currently, the mechanisms for the increased
progression are not known. However, according to the
two-hit hypothesis, the initial insult is the fat accumu-
lation within the liver, with the second insult being
increased oxidative stress and inflammation, and both
are critical for steatohepatitis.29 The current study
demonstrates that mice with a temporal hepatic dis-
ruption of Vhl have spontaneous fatty liver and liver
Fig. 5. HIF-2a increases angiopoietin-like 3
(Angptl3) expression in the liver. (A) qRT-PCR
analysis of Angptl3 in livers from VhlF/F and
VhlF/F;AlbERcre mice treated with tamoxifen and
killed 3, 7, or 14 days post-treatment. Expres-
sion was normalized to b-actin. Seven to nine
mice were assessed per each treatment
group. (B) Western blot analysis measuring
ANGPTL3 expression in livers from VhlF/F and
VhlF/F;AlbERcre mice treated with tamoxifen and
killed 14 days post-treatment. Expression was
normalized to GAPDH protein expression. (C)
Serum-triglyceride analysis measuring from
VhlF/F and VhlF/F;AlbERcre mice treated with ta-
moxifen and killed 14 days post-treatment.
Seven to nine mice were assessed per each
treatment group. (D) Hepa-1 cells were trans-
fected with increasing amounts of mouse
Angptl3. Forty-eight hours post-transfection,
cells were washed and stained with oil red O
or Western analysis performed to verify overex-
pression (top panel). Oil red O accumulation
was quantitated in isopropanolic extracts of
the cells, and data were normalized to protein
content (bottom panel). (E) Luciferase-reporter
constructs under the control of the (E) 1.7-kb
regulatory region of the mouse Angptl3 gene
or (F) 50 deletion constructs of the Angptl3
promoter. Hepa-1 cells transiently transfected
with the luciferase construct, and cotrans-
fected with empty vector, HIF-1a, or HIF-2a
expression plasmids. Standard dual-luciferase
assays were performed on cells incubated in
normal or hypoxic cell-culture conditions. Each
bar graph represents the mean value 6 SD.
OD, optical density; RLU, relative luciferase
units. *P < 0.05.
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inflammation that will progress to focal fibrosis and
hepatomegaly in a HIF-2a–dependent manner. This
demonstrates that hypoxia and HIF-2a play a critical
role in both insults needed for the progression of fatty
liver disease, as suggested by the two-hit hypothesis.
Gene-expression profiling demonstrated that several
genes important in fatty acid synthesis, uptake, and
b-oxidation are significantly altered after the loss of
VHL. Fasn and Srebp-1c were repressed in mice with a
conditional disruption of Vhl; therefore, fatty acid syn-
thesis was not thought to be involved in increased
lipid accumulation in the liver after Vhl disruption.14
However, the present data suggest that at early times
points, lipid synthesis may contribute to steatosis, as
both Fasn and Srebp-1c are significantly increased after
acute disruption, then are significantly repressed after
long-term Vhl deficiency. To assess whether, indeed, at
early time points after HIF activation that fatty acid
synthesis was increased, ACC activity was measured.
However, both phosphorylated and total ACC were
significantly repressed at 3 days after tamoxifen treat-
ment in the VhlF/F;AlbERcre mice, compared with VhlF/F
mice, making the data difficult to interpret (Support-
ing Fig. 5). However, 14 days after tamoxifen treat-
ment, no change in phosphorylated or total ACC was
observed in the VhlF/F;AlbERcre mice, compared with
VhlF/F mice, suggesting that b-oxidation may be a crit-
ical driver in fat accumulation at later time points. In
addition, the gene-expression analysis demonstrates a
significant modulation of several nuclear receptor tar-
get genes (e.g., liver X receptor, farnesoid X receptor,
and PPARc). However, changes were not found in the
expression of these nuclear receptors by qRT-PCR or
microarray analysis, suggesting that nuclear receptors
Fig. 6. Disruption of Vhl increases
liver fibrosis. (A) qRT-PCR analysis
measuring expression of fibrogenic
genes in livers of VhlF/F;AlbERcre or VhlF/F
mice treated with vehicle (VEH) or ta-
moxifen (TM) and killed 14 days post-
treatment. Expression was normalized
to b-actin. Seven to nine mice were
assessed per each treatment group.
(B) Western blot analysis measuring
SMA expression in livers from VhlF/F
and VhlF/F;AlbERcre mice treated with ta-
moxifen and killed 14 days post-treat-
ment. (C,D) Masson’s trichrome–stained
livers from VhlF/F and VhlF/F;AlbERcre
mice treated with tamoxifen and killed
14 days post-treatment on (C) normal
chow diet or (D) liquid alcohol diet.
Fibrotic cells are indicated by arrows or
are outlined by a dashed line. Seven to
nine mice were assessed per each
treatment group. Each bar graph repre-
sents the mean value 6 SD. *P <
0.05 and n ¼ 7-9 mice per each treat-
ment group.
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are not direct transcriptional targets of HIF. Interest-
ingly, in mice with the conditional Vhl deletion, adi-
pose differentiation-related protein (ADFP) was signifi-
cantly induced and thought to be critical in the liver
steatotic phenotype.14 However, in the VhlF/F;AlbERcre
mice after tamoxifen treatment, no increase in ADFP
was observed at any time point assessed (data not
shown), suggesting that the increase in ADFP is a late
secondary response or because of developmental
defects after conditional Vhl disruption. These data
highlight the importance of temporal gene disruption
of Vhl to identify direct mediators of response.
One important mediator of lipid homeostasis,
ANGPTL3, an endogenous lipoprotein lipase (LPL)
inhibitor,30-32 was identified as an HIF-responsive
gene. ANGPTL3 is important in regulating serum tri-
glycerides levels.20 In tamoxifen-treated VhlF/F;AlbERcre
mice, the increase of ANGPTL3 correlated to an
increase in serum triglycerides, and ANGPTL3 directly
increased lipid accumulation in Hepa-1 cells, as assessed
by oil red O staining. Currently, it is not known whether
the increase in lipid accumulation is through the LPL in-
hibitor function of ANGPTL3, but is a clear point of
emphasis for future studies. Angptl3 gene expression and
promoter activity were rapidly induced by HIF-2a.
However, no HREs were identified in the promoter, sug-
gesting that its activation is HIF-2a-mediated through
an indirect mechanism. The HIF-responsive region was
localized to a 100-bp region directly proximal to the
transcription initiation site, and HIF-2a regulation of
this sequence is being further assessed.
During the preparation of this article, others pub-
lished similar findings in a temporally deleted, liver-
specific VHL mouse model, in which disruption of Vhl
was induced by tail vein injection of adenovirus encoding
cre recombinase (ad-Cre).33 Five days after an injection
of ad-Cre, mice demonstrated dramatic steatosis and a
decrease in PPARa signaling, thus establishing, as does
the present study, that HIF signaling has a primary role
in liver lipid homeostasis. Furthermore, the present study
demonstrates that these are immediate, rapid responses of
HIF-2a signaling. Interestingly, after ad-Cre injection,
mice demonstrated rapid death in an HIF-dependent
manner, where the median survival was 6 days.34 The
increase in survival in the VhlF/F;AlbERcre mice after
tamoxifen administration allowed further assessment of
the livers, revealing increased progression of steatosis to
inflammation. Thus, VhlF/F;AlbERcre mice may be a valua-
ble model of spontaneous steatohepatitis for use in pre-
clinical drug development.
Although the direct effectors that increase inflamma-
tion are not known, it is possible that HIF-2a can
directly activate inflammatory mediators in the liver.
Indeed, it was shown that Il-6 is a direct HIF-2a tar-
get gene in macrophages.34 However, our data clearly
show that HIF-2a can bind to the promoters of several
profibrogenic genes, consistent with data demonstrat-
ing that hypoxia can activate fibrogenesis in hepato-
cytes and stellate cells.35-37 Hepatic stellate cells initiate
the fibrotic process. In the liver, quiescent stellate cells
are critical in the storage of vitamin A. During liver
injury, stellate cells become activated, proliferate, and
express a fibrogenic gene program.38 After Vhl disrup-
tion, a robust activation of stellate cells is observed in
the liver resulting from high activation of collagen
gene expression and an increase in SMA, both markers
of stellate cell activation. The initiating factor in the
activation of stellate cells after Vhl loss is thought to
Fig. 7. HIF-2a activation increases liver fibrosis. (A) Western blot
analysis of SMA from livers of VhlF/FHif1aF/F;AlbERcre and VhlF/F
Hif2aF/F;AlbERcre mice treated with tamoxifen (TM) and killed 14 days
post-treatment. Expression was normalized to GAPDH protein expres-
sion. (B) Masson’s trichrome–stained livers from VhlF/FHif1aF/F;AlbERcre
and VhlF/FHif2aF/F;AlbERcre mice treated with tamoxifen and killed 14
days post-treatment on a liquid alcohol diet. Fibrotic cells are indi-
cated by arrows or are outlined by a dashed line. Seven to nine mice
were assessed per each treatment group. (C) qRT-PCR analysis mea-
suring expression of fibrogenic genes in livers of VhlF/FHif1aF/F;AlbERcre
or VhlF/FHif2aF/F mice treated with tamoxifen (TM) and killed 14 days
post-treatment. Expression was normalized to b-actin. Seven to nine
mice were assessed per each treatment group. Each bar graph repre-
sents the mean value 6 SD. *P < 0.05.
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be the result of a sustained increase in lipid accumula-
tion and inflammatory genes. In addition, the increase
in fibrosis mediated by HIF-2a may be caused by col-
lagen matrix stabilization. P4HA1, P4HA2, and
PLOD2 are required for hydroxylation of lysyl and
prolyl residues on collagen.23,26 The resultant hydroxy-
lysyl and hydroxyproline groups are critical for the sta-
bility and synthesis of collagen matrixes. Loxl1 and
loxl2 gene expression were also increased in the livers
of tamoxifen-treated VhlF/F;AlbERcre mice, and their re-
spective promoters were occupied by HIF-2a. Lysyl
oxidase activity is critical in the formation of insoluble
collagen fibers, and HIF-1a has been shown to
increase renal fibrosis through a lysyl oxidase-mediated
mechanism.21,22 Moreover, TGM2, a multifunction
enzyme that covalently cross-links collagen matrices,
has been shown to be critical in inducing apoptosis by
inactivation of SP1 and c-met in injured livers after
alcohol administration.24,25 HIF-2a can directly regu-
late the promoter of Tgm2 in a distinct manner, as
observed with HIF-1a.39 It is not clear whether Tgm2
is the key enzyme that regulates fibrosis, because
Tgm2-null mice are not protected in the carbon tetra-
chloride and the thioacetamide-induced fibrosis mod-
els.40 However, it is likely that the cumulative increase
in several profibrogenic genes are needed to increase
liver fibrosis, and HIF-2a may be the critical transcrip-
tion factor to integrate these signals.
The present study demonstrates that activation of
HIF-2a in the liver regulates liver homeostasis and dis-
ease progression and establishes that steatosis, inflam-
mation, and fibrosis are direct responses initiated by
the liver after HIF-2a activation. In addition, the pres-
ent work provides a novel animal model to study the
Fig. 8. HIF-2a can directly bind to pro-
moters of fibrogenic genes in the liver. (A)
ChIP assays of livers from VhlF/F;AlbERcre or
VhlF/F treated with tamoxifen (TM) and killed
3 days post-treatment using HIF-2a-specific
antibody. Data are expressed as fold enrich-
ment over control immunoglobulin G (IgG) and
normalized to input. Seven to nine mice were
assessed per each treatment group. (B) West-
ern blot analysis measuring TGM2 expression
in livers from VhlF/F and VhlF/F;AlbERcre mice
treated with tamoxifen and killed 14 days
post-treatment. Expression was normalized to
GAPDH. (C) Luciferase-reporter constructs
under the control of the 1-kb regulatory region
of the mouse Tgm2 gene. Hepa-1 cells transi-
ently transfected with the luciferase construct
and cotransfected with empty vector, HIF-1a,
or HIF-2a expression plasmids. Standard
dual-luciferase assays were performed. (D)
Tgm2 promoter illustrating the HREs in the
regulatory region. Upstream regions are num-
bered in relation to the transcription initiation
site, which is designated þ1 (top panel).
HRE deleted Tgm2 luciferase-reporter was
cotransfected with empty vector or HIF-2a
expression plasmids (bottom panel). Standard
dual-luciferase assays were performed. (E)
ChIP assays of livers from VhlF/F;AlbERcre or
VhlF/F treated with tamoxifen (TM) and killed
3 days post-treatment using HIF-2a–specific
antibody. Primers flanking the two HREs were
used for PCR. Each bar graph represents the
mean value 6 SD. *P < 0.05. Three to five
mice were assessed per each treatment
group. RLU, relative luciferase units.
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precise molecular and genetic changes required for the
progression of fatty liver disease to steatohepatitis. To-
gether, these findings may lead to novel therapies for
liver injury.
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